Temporal relationship between thromboembolic events and myeloproliferative neoplasm diagnosis: is it associated with mortality risk?
E. Gulturk, D. Yılmaz, G. Bırce Sonmezoz, M. Dırıl Department of Hematology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. dr.denizyilmaz28@gmail.com
OBJECTIVE: The aim of this study is to investigate the temporal relationship between the first occurrence of thromboembolic events (TEE) and the timing of myeloproliferative neoplasm (MPN) diagnosis and to determine risk factors for TEE-related mortality in MPN.
PATIENTS AND METHODS: A total of 138 BCR-ABL-negative MPN patients with TEE, diagnosed from January 2010 to December 2019, were included in this retrospective cohort. Patients were compared according to mortality and subjects were classified into three groups with respect to having suffered index TEE before, during, or after MPN diagnosis.
RESULTS: The mean age of surviving patients was 57.5±13.8, while those who had died had a mean age of 72.0±9.0 (p<0.001). Males represented 56.5% of patients with mortality and 60.9% of those without mortality (p=0.876). TEE was detected in 26.0% of MPN patients, and TEE-related mortality rate was 16.7%. There was no relationship between mortality and the classification of patients according to index TEE (p =0.884). High age (p<0.001) and danazol use (p=0.014) were independently associated with TEE-related mortality.
CONCLUSIONS: The temporal relationship between TEE and MPN diagnosis was not found to influence mortality. Older patients and danazol recipients should be considered to have a higher risk of TEE-related mortality.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
E. Gulturk, D. Yılmaz, G. Bırce Sonmezoz, M. Dırıl
Temporal relationship between thromboembolic events and myeloproliferative neoplasm diagnosis: is it associated with mortality risk?
Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 11
Pages: 4942-4950
DOI: 10.26355/eurrev_202306_32611